Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 paclitaxel + vinorelbine in metastatic hormone-refractory prostate cancer
ACTRN12605000316606Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and vinorelbine in prostate cancer (PCa) and Metastatic Prostate Cancer (mPC), sponsored by Bristol Myers Squibb. Primary endpoint: PSA response. Started May 2004; status: completed.
02
Drugs
paclitaxelvinorelbine
03
Conditions
prostate cancer (PCa)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on ACTRN12605000316606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000316606.